The European Medicines Agency’s Committee for Medicinal Products for Human Use recommended five new products for approval, according to industry reports. Recommendations include a gene‑therapy milestone from Fondazione Telethon, and CHMP support for a Sanofi type 1 diabetes therapy and Eli Lilly’s oral SERD for a subset of breast cancers. The CHMP endorsements set up near‑term EMA decisions that could expand treatment options across rare disease and oncology indications. CHMP recommendations accelerate regulatory pathways in Europe and provide commercial clarity for sponsors preparing launches. The moves also reflect a wider regulatory push to evaluate diverse modalities — from gene therapies to oral targeted agents — under evolving benefit‑risk frameworks.